TickerGuard
Buy Day today: Good (62) Broad market participation · no major macro event
BSX

Boston Scientific Corp

Healthcare · Medical Devices

43.60$ -0.8% vs. previous close Closing price · As of: Sep 17, 2026

Ownership

Ownership Structure

Who owns Boston Scientific Corp (BSX)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 99.7% of the shares are freely tradable; institutional investors hold 94.9%.

Institutional ownership ?Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings. 94.9%
Insiders ?Share of the stock held by the executives, founders and major shareholders of the company itself. 0.2%
Float ?Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders. 99.7%
Short % of float ?Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices. 3.3%
Shares Outstanding ?Total number of shares issued. Price times share count gives market cap. 1,449Mio.

Largest Shareholders

Institutions

Institutions BSX
Name Stake (%) Shares Change (%) Date
BlackRock Inc 9.10 131,822,037 -3.1 03/31/2026
Vanguard Capital Management, LLC 6.65 96,411,568 +0.0 03/31/2026
FMR Inc 5.12 74,226,395 -23.8 03/31/2026
State Street Corp 4.69 67,986,847 +3.3 03/31/2026
PRIMECAP Management Company 3.49 50,520,914 +55.3 06/30/2026
JPMorgan Chase & Co 2.30 33,350,157 +31.4 03/31/2026
Geode Capital Management, LLC 2.30 33,285,757 +2.8 03/31/2026

Funds

Funds BSX
Name Stake (%) Shares Change (%) Date
Vanguard MStar Total Stk Mkt Idx Invest 3.27 47,324,803 +0.3 07/31/2026
Vanguard 500 Index Investor 2.69 39,020,916 +1.1 07/31/2026
Vanguard PRIMECAP Inv 2.13 30,883,039 +46.7 06/30/2026

Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.

Insider holdings

Insider holdings BSX
Person Role Shares Value As of Type
Mahoney Michael F Chairman, President & CEO 1,612,143 70,289,435 $ Aug 3, 2026 both
Fitzgerald Joseph Michael EVP & Group Pres, Cardiology 64,198 2,799,033 $ Jul 31, 2026 indirect
Ludwig Edward J Director 30,359 1,323,652 $ Jul 31, 2026 direct
Habiger David C Director 17,160 748,176 $ Aug 5, 2026 direct
Morano Susan E Director 13,784 600,982 $ Aug 25, 2026 direct
Monson Jonathan EVP and CFO 9,908 431,989 $ Aug 10, 2026 indirect
O'Connor Padraig Andrew EVP, Global Operations 7,892 344,091 $ Sep 2, 2026 direct
Woodworth Emily SVP, Global Controller and CAO 2,930 127,748 $ Aug 11, 2026 indirect

Holdings as of each person's most recent SEC Form 4 filing — excluding options and RSUs, which are not shares yet. Holdings may have changed between two filings.

Insiders

Insider Transactions

Insider Transactions
Date Person Role Type Shares Price Value
Sep 2, 2026 O'Connor Padraig Andrew EVP, Global Operations Other 567 48.37 27,426
Sep 2, 2026 O'Connor Padraig Andrew EVP, Global Operations Other 1,171 0.00
Aug 25, 2026 Morano Susan E Director Buy 2,040 49.22 100,408
Aug 11, 2026 Woodworth Emily SVP, Global Controller and CAO Other 2,930 51.19 149,987
Aug 10, 2026 Monson Jonathan EVP and CFO Other 9,908 50.46 499,958
Aug 5, 2026 Habiger David C Director Buy 2,100 47.59 99,937
Aug 4, 2026 Habiger David C Director Buy 140 48.59 6,802
Aug 3, 2026 Habiger David C Director Buy 1,042 48.07 50,084
Aug 3, 2026 Mahoney Michael F Chairman, President & CEO Other 22,119 48.43 1,071,223
Aug 3, 2026 Mahoney Michael F Chairman, President & CEO Buy 186,240 48.33 9,001,408
Jul 31, 2026 Ludwig Edward J Director Buy 5,000 45.48 227,400
Jul 31, 2026 Fitzgerald Joseph Michael EVP & Group Pres, Cardiology Other 64,198 46.73 2,999,973

Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character. View all insider transactions →

Data as of: September 17, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?